IMUNON Announces Data from Phase 1/2 Trial Evaluating Intraperitoneal IMNN-001 in Combination with Neoadjuvant Chemotherapy in Newly Diagnosed Patients with Advanced Epithelial Ovarian Cancer to be Published in Gynecologic Oncology

Core Insights - IMUNON, Inc. announced that data from its Phase 1/2 OVATION 2 trial will be published in the peer-reviewed journal Gynecologic Oncology and presented at the ASCO Annual Meeting on June 3, 2025, highlighting the significance of its findings in the treatment of advanced epithelial ovarian cancer [1][2][3][4] Company Overview - IMUNON is a clinical-stage biotechnology company focused on developing innovative treatments that utilize the body's natural mechanisms to generate effective responses against various diseases, differentiating itself from conventional therapies [9] - The company's lead clinical program, IMNN-001, is a DNA-based immunotherapy designed for localized treatment of advanced ovarian cancer, which has completed Phase 2 development [10] Study Details - The OVATION 2 study evaluated the safety and efficacy of intraperitoneal administration of IMNN-001 in combination with neoadjuvant and adjuvant chemotherapy in patients newly diagnosed with advanced epithelial ovarian cancer, enrolling 112 patients [5] - The study was an open-label trial that randomized patients 1:1 to receive either NACT plus IMNN-001 or standard-of-care NACT, with patients in the IMNN-001 arm receiving up to 17 weekly doses of 100 mg/m [5] Treatment Context - Epithelial ovarian cancer is the sixth deadliest malignancy among women in the U.S., with approximately 20,000 new cases annually, and about 70% diagnosed at advanced stages [7] - The disease is characterized by a high risk of recurrence, with a 75% recurrence rate in Stage III/IV patients, underscoring the need for new therapies that can improve overall survival [8] Technology Platform - IMNN-001 is developed using IMUNON's proprietary TheraPlas platform technology, which enables the delivery of IL-12, a potent cytokine that induces strong anticancer immunity [6] - The technology aims to provide localized treatment by instructing the body to produce cancer-fighting molecules at the tumor site, enhancing the therapeutic effect [10]